Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Short-term Investments (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Short-term Investments for 12 consecutive years, with $2.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Short-term Investments fell 96.49% to $2.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.4 million, a 96.49% decrease, with the full-year FY2024 number at $2.3 million, changed N/A from a year prior.
  • Short-term Investments was $2.4 million for Q3 2025 at Theravance Biopharma, down from $56.9 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $96.0 million in Q1 2021 to a low of $2.3 million in Q4 2024.
  • A 5-year average of $51.2 million and a median of $53.6 million in 2023 define the central range for Short-term Investments.
  • Peak YoY movement for Short-term Investments: skyrocketed 35.77% in 2023, then crashed 96.49% in 2025.
  • Theravance Biopharma's Short-term Investments stood at $94.8 million in 2021, then tumbled by 69.08% to $29.3 million in 2022, then soared by 112.6% to $62.3 million in 2023, then plummeted by 96.32% to $2.3 million in 2024, then rose by 4.23% to $2.4 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Short-term Investments are $2.4 million (Q3 2025), $56.9 million (Q2 2025), and $20.2 million (Q1 2025).